• Monopar named Jeffrey D. Kent as executive vice president, head of medical affairs, effective Sept. 1, 2026.
• Role centers on building medical affairs ahead of a potential U.S. FDA decision on the ALXN1840 NDA for Wilson disease.
• Kent was chief medical officer at Sling Therapeutics, leading a Phase 2b program for linsitinib in thyroid eye disease.
• He previously held senior medical affairs roles at Horizon Therapeutics, Abbott Laboratories, and Searle/Pharmacia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190800PRIMZONEFULLFEED9812449) on August 19, 2026, and is solely responsible for the information contained therein.